In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Microbot Medical Hopes To Bring First Disposable Endovascular Robot To US Market

Executive Summary

Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.

You may also be interested in...



Minute Insight: Stryker Partners With Microbot To Create Liberty Neurointervention Robot

The companies announced a strategic collaboration to integrate Stryker’s neurovascular instruments with Microbot’s Liberty robot to create procedure kits specifically for neurovascular interventions.

Corindus Sees ‘Silver Lining’ As Pandemic Shows Need For Remote Interventions

The Siemens Healthineers subsidiary is planning to create networks of CorPath GRX robotic intervention systems that will expand patient access to urgent interventions and reduce radiation exposure for both the patient and interventionalists.

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV125093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel